Free Trial
Want deep insights into your competitors & competitive landscape? Try Patsnap Eureka!

Top 10 New Entrants companies in Ribociclib
by Most Patent Filing In 1 Year in the world in 2018

The Ribociclib top 10 is Discovery PatSnap’ annual ranking of the top 10 Most Patent Filing In 1 Year Ribociclib New Entrants in the world. Discovery has identified the top key players, startups & unicorns, fast-growings, news entrants in 2018, ranking from differnt perspectives, including patent filing intensity, academic research capability, news media heat. The company list is generated from various data types.
Ribociclib (trade name Kisqali) is an inhibitor of cyclin D1/CDK4 and CDK6, and is used for the treatment of certain kinds of breast cancer. It is also being studied as a treatment for other drug-resistant cancers. It was developed by Novartis and Astex Pharmaceuticals.
#
Company Name
Region
Tech Topics
Total
1
Jiangsu Sheng, China
Contract research organization,Health care,Liposome,
...[+2]
Patent: 2
2
Noord-Brabant, Netherlands
Patent: 2
3
Pennsylvania, United States
Trade partner,Corporate social responsibility,Medicine,
...[+2]
Patent: 2
4
Taiwan Province, China
Patent: 2
5
Haryana, India
Patent: 2
6
Andhra Pradesh, India
Active ingredient,Radioimmunoassay,Diagnostic microbiology,
...[+2]
Patent: 1
7
Maharashtra, India
Patent: 1
8
Chongqing Shi, China
Patent: 1
9
Tennessee, United States
Patent: 1
10
China
Patent: 1
Page generation time: Jul 07 2025